| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_27e1ea5f65e8f958e48f1a9d53fdbb45 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24032
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-60 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-525
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4725
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-768
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-283
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70578 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-768 |
| filingDate |
2019-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c00694e56eb2d25b201fd4e9ef3bdd0d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d3966a198813bd27b6abf27c5b87ad23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d509ba1c6bae8d40d39916a60163903
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ed0ac9a96cb51db8c00d7b3a9fe69cb |
| publicationDate |
2020-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020051248-A1 |
| titleOfInvention |
Oncolytic virus platform to treat hematological cancer |
| abstract |
The disclosure provides Myxoma virus that expresses one or more immunomodulatory transgenes and its use in inhibiting and/or treating a hematological cancer in a subject. The disclosure also provides a leukocyte having a Myxoma virus that expresses one or more immunomodulatory transgenes and the use of the leukocyte for inhibiting and/or treating a hematological cancer in a subject. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3946373-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11117934-B2 |
| priorityDate |
2018-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |